Actively Recruiting

Phase Not Applicable
Age: 18Years - 68Years
All Genders
NCT07278115

Effects on Remission of Type 2 Diabetes Mellitus Following Gastric Bypass Alone vs Gastric Bypass Combined With Truncal Vagotomy

Led by University Research Institute for the Study of Genetic & Malignant Disorders in Childhood · Updated on 2026-04-30

40

Participants Needed

2

Research Sites

136 weeks

Total Duration

On this page

Sponsors

U

University Research Institute for the Study of Genetic & Malignant Disorders in Childhood

Lead Sponsor

N

National and Kapodistrian University of Athens

Collaborating Sponsor

AI-Summary

What this Trial Is About

This randomized, triple-blind clinical trial investigates whether adding truncal vagotomy to Roux-en-Y gastric bypass (RYGB) enhances remission of type 2 diabetes mellitus (T2DM) in patients with obesity. The study explores whether modulation of vagal signaling provides superior metabolic outcomes compared to standard RYGB alone. Background: RYGB is a proven metabolic procedure capable of inducing diabetes remission; however, the mechanisms remain incompletely defined. Emerging evidence supports a duodenum-centered neurohormonal model suggesting that amplified digestion-driven by vagal and hormonal hyperstimulation-plays a key role in the development of insulin resistance. The vagus nerve regulates pancreatic and biliary secretion, as well as gut hormone release. By combining truncal vagotomy with RYGB, the study aims to attenuate vagal overactivation and evaluate its impact on glucose homeostasis and hormonal adaptation. Design: Eligible adults (18-65 years) with BMI ≥30 kg/m² and confirmed T2DM (HbA1c ≥6.5%, or on antidiabetic therapy with HbA1c ≥6.1%) will be randomized to: 1. RYGB alone, or 2. RYGB with truncal vagotomy. Participants, postoperative staff, and assessors will remain blinded to allocation. Primary Outcome: Remission of T2DM at 12 months postoperatively, defined as fasting plasma glucose \<100 mg/dL and HbA1c \<6.0% without antidiabetic medication for at least one year. Secondary Outcomes: Changes in HbA1c, fasting glucose, insulin, C-peptide, OGTT-derived indices, GLP-1, CCK, PYY, GLP-2, oxyntomodulin responses, HOMA-IR, body composition, cardiovascular risk markers, medication use, and quality-of-life parameters. Surgical metrics include hospital stay, readmissions, complications, gastrointestinal symptoms, nutritional deficiencies, and bone density changes. Follow-Up: Assessments occur preoperatively and at 1, 3, 6, and 12 months after surgery. Significance: The VagusSx Trial tests whether targeted vagal and duodenal pathway interruption can improve glycemic control beyond weight loss alone, offering a novel, physiology-based strategy for durable diabetes remission.

CONDITIONS

Official Title

Effects on Remission of Type 2 Diabetes Mellitus Following Gastric Bypass Alone vs Gastric Bypass Combined With Truncal Vagotomy

Who Can Participate

Age: 18Years - 68Years
All Genders

Eligibility Criteria

Eligible

You may qualify if you...

  • BMI 30 kg/m² or higher
  • Age between 18 and 68 years
  • Confirmed type 2 diabetes mellitus with either HbA1c 6.5% or higher, or HbA1c 6.1% or higher while using antidiabetic medication
  • Advanced-DiaRem Score greater than 5
Not Eligible

You will not qualify if you...

  • Previous bariatric surgery or major abdominal surgery such as enterectomy, gastrectomy, colectomy, hepatectomy, or pancreatectomy
  • Major uncompensated health problems including serious psychiatric, endocrine, cardiac, pulmonary, hepatic, or renal disorders, cancer, or other high-risk conditions
  • Chronic corticosteroid use for more than 3 months within the last year or corticosteroid therapy within the last 3 months
  • Diagnosis of type 1 diabetes mellitus
  • Alcohol or drug addiction

AI-Screening

AI-Powered Screening

Complete this quick 3-step screening to check your eligibility

1
2
3
+1

Trial Site Locations

Total: 2 locations

1

Diabetes Surgery

Athens, Attica, Greece, 11527

Actively Recruiting

2

Diabetes Surgery

Athens, Attica, Greece, 11527

Not Yet Recruiting

Loading map...

Research Team

A

Athena N Kapralou, MD, PhD

CONTACT

How is the study designed?

Study Type

INTERVENTIONAL

Masking

TRIPLE

Allocation

RANDOMIZED

Model

PARALLEL

Primary Purpose

TREATMENT

Number of Arms

2

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here